StreetInsider.com News Articles

Form 8-K TuHURA Biosciences, Inc. For: Sep 21

Thu, 24 Sep 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260924/27102809.html

TuHURA Biosciences (HURA) Reiterates at Market Outperform by Citizens on TBS-2025 Development

Wed, 23 Sep 2026 04:45:26 -0400

Citizens analyst Silvan Turkcan reiterated a Market Outperform rating and $9.00 price target on TuHURA Biosciences (NASDAQ: HURA).

The analyst commented, "TuHURA is developing TBS-2025, a VISTA-inhibiting mAb in AML, rather than in solid tumors, where this checkpoint may be driving acquired resistance, especially in NPM1- mutated AML. TuHURA (Kineta) designed TBS-2025 to address shortcomings that have plagued prior VISTA mAbs that were developed in solid tumors: 1) longer half-life enables Q2W dosing with optimal receptor occupancy; and 2) improved alignment with VISTA biology, expanding the previously constrained therapeutic window, driven by cytokine release syndrome (CRS). The trial covers a large

Form 8-K TuHURA Biosciences, Inc. For: Sep 14

Thu, 17 Sep 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260917/27076657.html

Form 8-K/A TuHURA Biosciences, Inc. For: Sep 10

Thu, 17 Sep 2026 09:00:00 -0400

si-local-file:///var/storage/secattach/20260917/27073547.html

Form 8-K TuHURA Biosciences, Inc. For: Sep 10

Wed, 16 Sep 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260916/27071024.html

TuHURA Biosciences gets FDA clearance to trial AML antibody

Mon, 14 Sep 2026 07:46:06 -0400

TuHURA Biosciences, Inc. (NASDAQ: HURA) announced that the U.S. Food and Drug Administration has cleared the company's Investigational New Drug application for TBS-2025, a VISTA-inhibiting monoclonal antibody, allowing a Phase 1b clinical study to proceed in patients with certain blood-related cancers.

The FDA's "Study May Proceed" notice permits TuHURA to evaluate TBS-2025 as a monotherapy at varying doses in patients with relapsed or refractory mutNPM1 Acute Myeloid Leukemia (AML) who have not responded to or have relapsed after menin inhibitor therapy. The company said patients in this category currently have no approved or effective treatment options.

The Phase 1b study will initially

TuHURA Biosciences gets FDA clearance to trial AML antibody

Mon, 14 Sep 2026 07:46:06 -0400

The Phase 1b study will initially

TuHURA Biosciences Receives FDA "Study May Proceed" Notice and IND Clearance for the Evaluation of its TBS-2025 VISTA-Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Bloo

Mon, 14 Sep 2026 07:45:00 -0400

TAMPA, Fla., Sept. 14, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that the U.S. Food and Drug Administration (FDA) has given clearance to TuHURA's Investigational New Drug (IND) application for its TBS-2025 VISTA-inhibiting antibody for molecularly defined subsets of Acute Myeloid Leukemia (AML) and other blood-related cancers.

TuHURA Biosciences Receives FDA "Study May Proceed" Notice and IND Clearance for the Evaluation of its TBS-2025 VISTA-Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Bloo

Mon, 14 Sep 2026 07:45:00 -0400

TuHURA Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Tue, 08 Sep 2026 07:45:00 -0400

TAMPA, Fla., Sept. 8, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that James A. Bianco, M.D., President and Chief Executive Officer of TuHURA will present at the H.C. Wainwright 28^th Annual Global Investment Conference in New York, NY.

H.C. Wainwright 28^th Annual Global Investment Conference

Date:

TuHURA Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Tue, 08 Sep 2026 07:45:00 -0400

H.C. Wainwright 28^th Annual Global Investment Conference

Date:

Form SCHEDULE 13D/A TuHURA Biosciences, Inc. Filed by: Bianco James A.

Fri, 28 Aug 2026 18:02:00 -0400

si-local-file:///var/storage/secattach/20260828/26999265.html

Form SCHEDULE 13D/A TuHURA Biosciences, Inc. Filed by: Bianco James A.

Fri, 28 Aug 2026 18:02:00 -0400

si-local-file:///var/storage/secattach/20260828/26999265.html

Form 8-K TuHURA Biosciences, Inc. For: Aug 20

Fri, 21 Aug 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260821/26962307.html

Form 8-K TuHURA Biosciences, Inc. For: Aug 20

Fri, 21 Aug 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260821/26962307.html

Form 8-K TuHURA Biosciences, Inc. For: Aug 18

Wed, 19 Aug 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260819/26950949.html

Form 8-K TuHURA Biosciences, Inc. For: Aug 18

Wed, 19 Aug 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260819/26950949.html

TuHURA Biosciences (HURA) Reiterated at Market Outperform by Citizens

Tue, 18 Aug 2026 04:15:50 -0400

Citizens analyst Silvan Turkcan reiterated a Market Outperform rating and $9.00 price target on TuHURA Biosciences (NASDAQ: HURA).

The analyst commented, "TuHURA is focused on several novel approaches based on myeloid biology as well as a legacy product in Phase 3 development. Development of IFx-2.0 is ongoing and HURA has an aligned with the FDA on a path to the market that includes the potential to reach the market without a confirmatory study, based on PFS data of the Phase 3. TuHura's next-generation assets focus on a novel approach to AML, via targeting of immunosuppresive phenotype and reprogramming of the TME.

Form 10-Q TuHURA Biosciences, Inc. For: Jun 30

Fri, 14 Aug 2026 08:02:00 -0400

si-local-file:///var/storage/secattach/20260814/26924845.html

Form 10-Q TuHURA Biosciences, Inc. For: Jun 30

Fri, 14 Aug 2026 08:02:00 -0400

si-local-file:///var/storage/secattach/20260814/26924845.html

Form 8-K TuHURA Biosciences, Inc. For: Aug 14

Fri, 14 Aug 2026 07:50:00 -0400

si-local-file:///var/storage/secattach/20260814/26924672.html

Form 8-K TuHURA Biosciences, Inc. For: Aug 14

Fri, 14 Aug 2026 07:50:00 -0400

si-local-file:///var/storage/secattach/20260814/26924672.html

TuHURA Biosciences Reports Second Quarter 2026 Financial Results and Provides a Corporate Update

Fri, 14 Aug 2026 07:45:00 -0400

TAMPA, Fla., Aug. 14, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today reported financial results for the Company's second quarter ended June 30, 2026, and provided a corporate update.

"We have made significant progress in advancing all our programs forward and are positioned to continue driving towards several anticipated milestones targeted for the second half of the year," said Dr. James Bianco, President and CEO of TuHURA Biosciences. "In the second

TuHURA Biosciences Reports Second Quarter 2026 Financial Results and Provides a Corporate Update

Fri, 14 Aug 2026 07:45:00 -0400

TuHURA Biosciences Reports Second Quarter 2026 Financial Results and Provides a Corporate Update

Fri, 14 Aug 2026 07:45:00 -0400